Literature DB >> 19279310

Severe molecular defects of a novel FOXC1 W152G mutation result in aniridia.

Yoko A Ito1, Tim K Footz, Fred B Berry, Farideh Mirzayans, May Yu, Arif O Khan, Michael A Walter.   

Abstract

PURPOSE: FOXC1 mutations result in Axenfeld-Rieger syndrome, a disorder characterized by a broad spectrum of malformations of the anterior segment of the eye and an elevated risk for glaucoma. A novel FOXC1 W152G mutation was identified in a patient with aniridia. Molecular analysis was conducted to determine the functional consequences of the FOXC1 W152G mutation.
METHODS: Site-directed mutagenesis was used to introduce the W152G mutation into the FOXC1 complementary DNA. The levels of W152G protein expression and the functional abilities of the mutant protein were determined.
RESULTS: After screening for mutations in PAX6, CYP1B1, and FOXC1, a novel FOXC1 W152G mutation was identified in a newborn boy with aniridia and congenital glaucoma. Molecular analysis of the W152G mutation revealed that the mutant protein has severe molecular consequences in FOXC1, including defects in phosphorylation, protein folding, DNA-binding ability, inability to transactivate a reporter gene, and nuclear localization. Although W152G has molecular defects similar to those of the previously studied FOXC1 L130F mutation, W152G causes a more severe phenotype than L130F. Both the W152G and the L130F mutations result in the formation of protein aggregates in the cytoplasm. However, unlike the L130F aggregates, the W152G aggregates do not form microtubule-dependent inclusion bodies, known as aggresomes.
CONCLUSIONS: Severe molecular consequences, including the inability of the W152G protein aggregates to form protective aggresomes, may underlie the aniridia phenotype that results from the FOXC1 W152G mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279310     DOI: 10.1167/iovs.08-3032

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  25 in total

1.  Clinical utility gene card for: Axenfeld-Rieger syndrome.

Authors:  Nicole Weisschuh; Elfride De Baere; Bernd Wissinger; Zeynep Tümer
Journal:  Eur J Hum Genet       Date:  2010-10-13       Impact factor: 4.246

2.  Disruption of foxc1 genes in zebrafish results in dosage-dependent phenotypes overlapping Axenfeld-Rieger syndrome.

Authors:  Jesús-José Ferre-Fernández; Elena A Sorokina; Samuel Thompson; Ross F Collery; Emily Nordquist; Joy Lincoln; Elena V Semina
Journal:  Hum Mol Genet       Date:  2020-09-29       Impact factor: 6.150

Review 3.  Aniridia.

Authors:  Melanie Hingorani; Isabel Hanson; Veronica van Heyningen
Journal:  Eur J Hum Genet       Date:  2012-06-13       Impact factor: 4.246

4.  Oncogenic Mutations in the DNA-Binding Domain of FOXO1 that Disrupt Folding: Quantitative Insights from Experiments and Molecular Simulations.

Authors:  Dylan Novack; Lei Qian; Gwyneth Acker; Vincent A Voelz; Richard H G Baxter
Journal:  Biochemistry       Date:  2022-07-27       Impact factor: 3.321

Review 5.  Childhood glaucoma genes and phenotypes: Focus on FOXC1 mutations causing anterior segment dysgenesis and hearing loss.

Authors:  Angela C Gauthier; Janey L Wiggs
Journal:  Exp Eye Res       Date:  2019-12-11       Impact factor: 3.467

6.  Clinical utility gene card for: Aniridia.

Authors:  Rose Richardson; Melanie Hingorani; Veronica Van Heyningen; Cheryl Gregory-Evans; Mariya Moosajee
Journal:  Eur J Hum Genet       Date:  2016-07-06       Impact factor: 4.246

7.  Genetic and genomic analysis of classic aniridia in Saudi Arabia.

Authors:  Arif O Khan; Mohammed A Aldahmesh; Fowzan S Alkuraya
Journal:  Mol Vis       Date:  2011-03-11       Impact factor: 2.367

8.  Mutation spectrum of PAX6 in Chinese patients with aniridia.

Authors:  Xiaohui Zhang; Panfeng Wang; Shiqiang Li; Xueshan Xiao; Xiangming Guo; Qingjiong Zhang
Journal:  Mol Vis       Date:  2011-08-11       Impact factor: 2.367

9.  Asymmetric phenotype of Axenfeld-Rieger anomaly and aniridia associated with a novel PITX2 mutation.

Authors:  Simon K Law; Maha Sami; Natik Piri; Anne L Coleman; Joseph Caprioli
Journal:  Mol Vis       Date:  2011-05-06       Impact factor: 2.367

10.  Eye anomalies and neurological manifestations in patients with PAX6 mutations.

Authors:  Yin-Hsuan Chien; Hsiang-Po Huang; Wuh-Liang Hwu; Yin-Hsiu Chien; Tseng-Ching Chang; Ni-Chung Lee
Journal:  Mol Vis       Date:  2009-10-22       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.